Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC

NCT05056337 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

220

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: Lenvatinib 4 MG Oral Capsule [Lenvima]
DRUG: Toripalimab
PROCEDURE: TACE

Sponsor

Shanghai Zhongshan Hospital